Getting under the skin: The role of CDK4/6 in melanomas
- 1 October 2020
- journal article
- review article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 204, 112531
Abstract
No abstract availableKeywords
Funding Information
- Sichuan University
This publication has 83 references indexed in Scilit:
- The Anti-Melanoma Activity of Dinaciclib, a Cyclin-Dependent Kinase Inhibitor, Is Dependent on p53 SignalingPLOS ONE, 2013
- The CDK Network: Linking Cycles of Cell Division and Gene ExpressionGenes & Cancer, 2012
- Cyclin-Dependent Kinase 7/9 Inhibitor SNS-032 Abrogates FIP1-like-1 Platelet-Derived Growth Factor Receptor α and Bcr-Abl Oncogene Addiction in Malignant Hematologic CellsClinical Cancer Research, 2012
- Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: A study of 522 consecutive casesBMC Cancer, 2011
- Nuclear Cyclin D1/CDK4 Kinase Regulates CUL4 Expression and Triggers Neoplastic Growth via Activation of the PRMT5 MethyltransferaseCancer Cell, 2010
- Inhibition of Mutated, Activated BRAF in Metastatic MelanomaNew England Journal of Medicine, 2010
- AT7519, a Cyclin-Dependent Kinase Inhibitor, Exerts Its Effects by Transcriptional Inhibition in Leukemia Cell Lines and Patient SamplesMolecular Cancer Therapeutics, 2010
- Estimating CDKN2A Carrier Probability and Personalizing Cancer Risk Assessments in Hereditary Melanoma Using MelaPROCancer Research, 2010
- Reduced expression of p16 and p27 is correlated with tumour progression in cutaneous melanomaPathology, 2007
- Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continentsJournal of Medical Genetics, 2006